Stem definition | Drug id | CAS RN |
---|---|---|
prostaglandins | 343 | 88430-50-6 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 19 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.01 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 1, 1992 | YEAR INTRODUCED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pulmonary hypertension | 136.53 | 27.91 | 56 | 2884 | 35888 | 56253239 |
Pulmonary arterial hypertension | 123.97 | 27.91 | 48 | 2892 | 26455 | 56262672 |
Cardiac failure | 116.63 | 27.91 | 65 | 2875 | 82028 | 56207099 |
Concomitant disease aggravated | 105.78 | 27.91 | 32 | 2908 | 8394 | 56280733 |
Right ventricular failure | 99.69 | 27.91 | 36 | 2904 | 16343 | 56272784 |
Transfusion | 79.59 | 27.91 | 29 | 2911 | 13491 | 56275636 |
Brain natriuretic peptide increased | 77.11 | 27.91 | 22 | 2918 | 4704 | 56284423 |
Upper respiratory tract inflammation | 66.11 | 27.91 | 17 | 2923 | 2460 | 56286667 |
Hepatic function abnormal | 64.87 | 27.91 | 33 | 2907 | 34525 | 56254602 |
Anaemia | 63.95 | 27.91 | 74 | 2866 | 267437 | 56021690 |
Iron deficiency anaemia | 51.66 | 27.91 | 23 | 2917 | 17896 | 56271231 |
Platelet count decreased | 50.79 | 27.91 | 43 | 2897 | 106340 | 56182787 |
Gamma-glutamyltransferase increased | 50.70 | 27.91 | 27 | 2913 | 30978 | 56258149 |
Blood pressure decreased | 41.46 | 27.91 | 30 | 2910 | 59020 | 56230107 |
Aspartate aminotransferase increased | 34.57 | 27.91 | 31 | 2909 | 82571 | 56206556 |
Pulmonary arterial pressure increased | 34.57 | 27.91 | 11 | 2929 | 3394 | 56285733 |
Red blood cell count decreased | 33.72 | 27.91 | 22 | 2918 | 36595 | 56252532 |
Haematocrit decreased | 33.60 | 27.91 | 22 | 2918 | 36807 | 56252320 |
Renal impairment | 33.20 | 27.91 | 30 | 2910 | 80683 | 56208444 |
Interstitial lung disease | 31.24 | 27.91 | 25 | 2915 | 57038 | 56232089 |
Haemoglobin decreased | 30.07 | 27.91 | 36 | 2904 | 134101 | 56155026 |
Fatigue | 28.10 | 27.91 | 4 | 2936 | 788548 | 55500579 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pulmonary arterial hypertension | 101.16 | 31.17 | 30 | 1223 | 9791 | 31686300 |
Right ventricular failure | 88.34 | 31.17 | 26 | 1227 | 8256 | 31687835 |
Concomitant disease aggravated | 76.44 | 31.17 | 21 | 1232 | 5203 | 31690888 |
Cardiac failure | 55.20 | 31.17 | 37 | 1216 | 85916 | 31610175 |
Pulmonary hypertension | 52.10 | 31.17 | 22 | 1231 | 20019 | 31676072 |
Brain natriuretic peptide increased | 50.60 | 31.17 | 15 | 1238 | 4861 | 31691230 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pulmonary arterial hypertension | 200.44 | 28.78 | 76 | 4398 | 32779 | 70891191 |
Pulmonary hypertension | 178.11 | 28.78 | 77 | 4397 | 46459 | 70877511 |
Right ventricular failure | 174.62 | 28.78 | 62 | 4412 | 22212 | 70901758 |
Concomitant disease aggravated | 172.75 | 28.78 | 53 | 4421 | 12061 | 70911909 |
Cardiac failure | 145.36 | 28.78 | 98 | 4376 | 143443 | 70780527 |
Brain natriuretic peptide increased | 121.79 | 28.78 | 37 | 4437 | 8134 | 70915836 |
Transfusion | 81.34 | 28.78 | 34 | 4440 | 18802 | 70905168 |
Upper respiratory tract inflammation | 76.92 | 28.78 | 22 | 4452 | 3920 | 70920050 |
Hepatic function abnormal | 74.87 | 28.78 | 49 | 4425 | 67947 | 70856023 |
Anaemia | 69.99 | 28.78 | 105 | 4369 | 403318 | 70520652 |
Iron deficiency anaemia | 59.31 | 28.78 | 29 | 4445 | 23043 | 70900927 |
Platelet count decreased | 57.12 | 28.78 | 63 | 4411 | 178159 | 70745811 |
Gamma-glutamyltransferase increased | 42.71 | 28.78 | 31 | 4443 | 50654 | 70873316 |
Blood pressure decreased | 37.62 | 28.78 | 37 | 4437 | 91478 | 70832492 |
Aspartate aminotransferase increased | 37.41 | 28.78 | 43 | 4431 | 126935 | 70797035 |
Interstitial lung disease | 35.22 | 28.78 | 38 | 4436 | 104647 | 70819323 |
Pulmonary arterial pressure increased | 33.74 | 28.78 | 12 | 4462 | 4297 | 70919673 |
Fatigue | 31.19 | 28.78 | 7 | 4467 | 824312 | 70099658 |
Red blood cell count decreased | 31.09 | 28.78 | 26 | 4448 | 52135 | 70871835 |
Alanine aminotransferase increased | 30.73 | 28.78 | 42 | 4432 | 147438 | 70776532 |
Haemoglobin decreased | 30.68 | 28.78 | 50 | 4424 | 205109 | 70718861 |
None
Source | Code | Description |
---|---|---|
ATC | B01AC19 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D006401 | Hematologic Agents |
MeSH PA | D010975 | Platelet Aggregation Inhibitors |
MeSH PA | D014665 | Vasodilator Agents |
CHEBI has role | CHEBI:35620 | vasodilator agents |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
CHEBI has role | CHEBI:66900 | prostaglandin receptor agonists |
CHEBI has role | CHEBI:67079 | anti-inflammatory agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pulmonary arterial hypertension | indication | 11399002 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.76 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostacyclin receptor | GPCR | AGONIST | IC50 | 8.37 | WOMBAT-PK | DRUG LABEL | |||
Prostaglandin E2 receptor EP3 subtype | GPCR | AGONIST | Ki | 6.17 | IUPHAR | ||||
Prostaglandin E2 receptor EP4 subtype | GPCR | AGONIST | Ki | 5.14 | IUPHAR | ||||
Prostacyclin receptor | GPCR | AGONIST | Ki | 7.80 | IUPHAR | ||||
Prostacyclin receptor | GPCR | AGONIST | Ki | 7.72 | IUPHAR |
ID | Source |
---|---|
D01551 | KEGG_DRUG |
88475-69-8 | SECONDARY_CAS_RN |
C0053336 | UMLSCUI |
CHEBI:135633 | CHEBI |
CHEMBL1207745 | ChEMBL_ID |
CHEMBL435883 | ChEMBL_ID |
DB05229 | DRUGBANK_ID |
C048081 | MESH_SUPPLEMENTAL_RECORD_UI |
6917951 | PUBCHEM_CID |
1967 | IUPHAR_LIGAND_ID |
6261 | INN_ID |
35E3NJJ4O6 | UNII |
010867 | NDDF |
010868 | NDDF |
None